Our top pick for
Genesis Healthcare, Inc (GEN) is a leading medical care facilities business based in the US. It opened the day at USD$0.485 after a previous close of USD$0.4744. During the day the price has varied from a low of USD$0.48 to a high of USD$0.5597. The latest price was USD$0.5113 (25 minute delay). Genesis Healthcare is listed on the NYSE and employs 55,000 staff. All prices are listed in US Dollars.
|52-week range||USD$0.4 - USD$1.71|
|50-day moving average||USD$0.8215|
|200-day moving average||USD$0.6173|
|Wall St. target price||USD$0.53|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.245|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Genesis Healthcare stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genesis Healthcare's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Genesis Healthcare's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Genesis Healthcare shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Genesis Healthcare's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$160.9 million.
The EBITDA is a measure of a Genesis Healthcare's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$4.1 billion|
|Gross profit TTM||USD$2.1 billion|
|Return on assets TTM||-2.54%|
|Return on equity TTM||0%|
|Market capitalisation||USD$135.3 million|
TTM: trailing 12 months
There are currently 1.2 million Genesis Healthcare shares held short by investors – that's known as Genesis Healthcare's "short interest". This figure is 173.1% up from 430,547 last month.
There are a few different ways that this level of interest in shorting Genesis Healthcare shares can be evaluated.
Genesis Healthcare's "short interest ratio" (SIR) is the quantity of Genesis Healthcare shares currently shorted divided by the average quantity of Genesis Healthcare shares traded daily (recently around 5.9 million). Genesis Healthcare's SIR currently stands at 0.2. In other words for every 100,000 Genesis Healthcare shares traded daily on the market, roughly 200 shares are currently held short.
However Genesis Healthcare's short interest can also be evaluated against the total number of Genesis Healthcare shares, or, against the total number of tradable Genesis Healthcare shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genesis Healthcare's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Genesis Healthcare shares in existence, roughly 10 shares are currently held short) or 0.015% of the tradable shares (for every 100,000 tradable Genesis Healthcare shares, roughly 15 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Genesis Healthcare.
Find out more about how you can short Genesis Healthcare stock.
We're not expecting Genesis Healthcare to pay a dividend over the next 12 months.
Genesis Healthcare's shares were split on a 10:11 basis on 4 April 2013. So if you had owned 11 shares the day before before the split, the next day you'd have owned 10 shares. This wouldn't directly have changed the overall worth of your Genesis Healthcare shares – just the quantity. However, indirectly, the new 10% higher share price could have impacted the market appetite for Genesis Healthcare shares which in turn could have impacted Genesis Healthcare's share price.
Over the last 12 months, Genesis Healthcare's shares have ranged in value from as little as $0.4 up to $1.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Genesis Healthcare's is 1.3447. This would suggest that Genesis Healthcare's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Genesis Healthcare, Inc., together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services; Rehabilitation Therapy Services; and Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy. In addition, the company offers other specialty medical services, such as physician, staffing, and other healthcare related services. As of April 23, 2020, it provided inpatient services through a network of approximately 400 skilled nursing facilities and assisted/senior living communities in 25 states; and supplied rehabilitation and respiratory therapy to approximately 1,200 healthcare locations in 44 states, the District of Columbia and China. The company was formerly known as FC-GEN Operations Investment, LLC and changed its name to Genesis HealthCare, Inc. in February 2015. Genesis HealthCare, Inc. was founded in 2003 and is headquartered in Kennett Square, Pennsylvania.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.